For research use only. Not for therapeutic Use.
Anle138b（Cat No.:I013551） is a novel compound that acts as an oligomer modulator and aggregation inhibitor. It effectively prevents the formation of pathological aggregates of prion protein (PrP(Sc)) and α-synuclein (α-syn), which are implicated in neurodegenerative diseases. Anle138b possesses favorable properties such as good oral bioavailability, permeability across the blood-brain barrier, and no detectable toxicity. These characteristics make Anle138b a promising candidate for disease-modifying treatments in neurodegenerative disorders like prion diseases and Parkinson’s disease.
| Catalog Number | I013551 |
| CAS Number | 882697-00-9 |
| Molecular Formula | C₁₆H₁₁BrN₂O₂ |
| Purity | ≥95% |
| Target | Others |
| Solubility | DMSO |
| Storage | 2-8°C |
| IUPAC Name | 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole |
| InChI | InChI=1S/C16H11BrN2O2/c17-12-3-1-2-10(6-12)13-8-14(19-18-13)11-4-5-15-16(7-11)21-9-20-15/h1-8H,9H2,(H,18,19) |
| InChIKey | RCQIIBJSUWYYFU-UHFFFAOYSA-N |
| SMILES | C1OC2=C(O1)C=C(C=C2)C3=CC(=NN3)C4=CC(=CC=C4)Br |
| Reference | [1]. Wagner J, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson//’s disease. Acta Neuropathol. 2013 Jun;125(6):795-813.<br>[2]. Wagner J, et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015 Nov;130(5):619-31. |
